We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Generates Stem Cells Without Harming Embryos

By Biotechdaily staff writers
Posted on 08 Sep 2006
Scientists using a new technique report that they have been able to generate human embryonic stem cells (hES) by using a single-cell biopsy that they say does not harm embryos. More...
The technique was described in the August 24, 2006, online edition of Nature.

The technique, called preimplantation genetic diagnosis (PGD), is similar to the technique used in in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos. The resulting cell lines appear to be identical to hES cell lines derived from later-stage embryos using techniques that destroy the embryo's developmental potential. Current technology derives hES cells from the inner cell mass of later-stage embryos known as blastocysts, destroying their potential for further development. The new technique generates hES from a single cell obtained from an eight-cell-stage embryo.

To create the new cell lines, researchers at Advanced Cell Technology (ACT, Alameda, CA, USA) used single cells obtained from unused embryos produced by IVF for clinical purposes. Nineteen stem-cell outgrowths and two stable hES cell lines were obtained. The lines were genetically normal and retained their potential to form all of the cells in the human body.

"We have demonstrated, for the first time, that human embryonic stem cells can be generated without interfering with the embryo's potential for life,” said senior author Robert Lanza, M.D., vice president of research & scientific development at ACT. "Overnight cultures of a single cell obtained through biopsy allow both PGD and the development of stem-cell lines without affecting the subsequent chances of having a child. To date, more than 1,500 healthy children have been born following the use of PGD.”

Those with ethical concerns see problems with the technique. They fear that removing one cell from an embryo is likely to lower the embryo's chances of womb implantation or may alter its development in some way and later cause health problems in the child developed from it. Some critics fear that the cell that is removed may have its potential for developing into a new embryo destroyed. Thus, the new technique joins a long list of others designed to avoid controversy but still posing problems.

"None of those methods was likely to satisfy all the critics, and I don't think this one will either,” said Tom Murray, president of the Hastings Center, a bioethics research institute in Garrison (NY, USA).



Related Links:
Advanced Cell Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.